(Q35227792)

7 August 2017

title

Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial (English)

1 reference

7 August 2017

main subject

metastatic breast cancer

1 reference

1 reference

Michael Fiegl

1

1 reference

7 August 2017

Brigitte Mlineritsch

2

1 reference

7 August 2017

Michael Hubalek

3

1 reference

7 August 2017

Rupert Bartsch

4

1 reference

7 August 2017

Ursula Pluschnig

5

1 reference

7 August 2017

Günther G Steger

6

1 reference

7 August 2017

language of work or name

English

0 references

publication date

24 August 2011

1 reference

7 August 2017

1 reference

7 August 2017

volume

11

1 reference

7 August 2017

page(s)

373

1 reference

Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials

7 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3178544

A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3178544

Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3178544

Third consensus on medical treatment of metastatic breast cancer.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3178544

Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3178544

Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3178544

The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3178544

Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc., experience

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3178544

Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma

27 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-373

Phase II study of single-agent pegylated liposomal doxorubicin HCl (PLD) in metastatic breast cancer after first-line treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-373

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-373

Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-373

A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-373

Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-373

Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-373

The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-373

Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-373

Holding back the sea: the role for maintenance chemotherapy in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-373

Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-373

Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-373

Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21864402

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21864402

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21864402

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-2407-11-373

1 reference

Dimensions Publication ID

7 August 2017

0 references

1 reference

7 August 2017

1 reference